课题基金 / 基金详情

Pseudotype Production Optimization

Pseudotype Production Optimization
伪型生产优化
批准号:
6583151
负责人:
Benjamin Jacob Doranz
金额:
$45.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-02-15 至 2005-01-31

项目摘要

项目成果

Benjamin Jacob Doranz的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):
英文摘要
DESCRIPTION (provided by applicant): ViraCore is a tool-based biotechnology company that is creating a drug discovery platform for use by the pharmaceutical and biotechnology industries. ViraCore is developing "lipoparticles", nanometer-sized particles surrounded by a lipid bilayer and embedded with membrane-bound receptors, to purify and solubilize complex receptors from the cell surface while maintaining their structural integrity. ViraCore intends to leverage this technology for drug discovery and research of integral membrane proteins on biosensors and other microfluidic devices. Approximately half of the drugs in use today target membrane proteins, including G-protein coupled receptors. The purpose of this proposal is to scale lipoparticle production techniques, modify and improve lipoparticle properties, begin development of second-generation lipoparticles with unique capabilities, and validate lipoparticles for drug discovery applications. The goals of this proposal are to: - Optimize Commercial Manufacture Protocols - Develop Second- generation Lipoparticles - Improve Lipoparticle Composition - Validate Lipoparticles as Drug Screening Reagents
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease
  • 批准号:
    10624244
  • 项目类别:
  • 资助金额:
    $8.9万
  • 财政年份:
    2022
  • 负责人:
    Benjamin Jacob Doranz
  • 依托单位:
Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease
  • 批准号:
    10383454
  • 项目类别:
  • 资助金额:
    $35.86万
  • 财政年份:
    2022
  • 负责人:
    Benjamin Jacob Doranz
  • 依托单位:
Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases
  • 批准号:
    9766179
  • 项目类别:
  • 资助金额:
    $20.38万
  • 财政年份:
    2018
  • 负责人:
    Benjamin Jacob Doranz
  • 依托单位:
Development of CB1 Monoclonal Antibodies for Treating NASH
  • 批准号:
    9918931
  • 项目类别:
  • 资助金额:
    $33.95万
  • 财政年份:
    2018
  • 负责人:
    Benjamin Jacob Doranz
  • 依托单位:
海外基金